Pathstone Family Office, LLC Ultragenyx Pharmaceutical Inc. Call Options Transaction History
Pathstone Family Office, LLC
- $15.6 Billion
- Q3 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RARE
# of Institutions
335Shares Held
88.9MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$362 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$203 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$151 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$116 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$94.8 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.53B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...